In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China
In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China
复制标题
泰地唑胺与其他抗生素对中国26家医院医院获得性肺炎、皮肤软组织感染和血流感染相关革兰氏阳性病原体的体外活性比较
DOI：
10.1099/jmm.0.000347
复制
发表时间：
2016-10-01
影响因子：
3
通讯作者：
Wang, Hui
中科院分区：
文献类型：
--
作者：
Li, Shuguang;Guo, Yu;Wang, Hui
为了评价替地唑胺、利奈唑胺和其他对照药物对来自医院获得性肺炎（HAP）、皮肤和软组织感染（SSTI）和血流感染（BSI）的具有临床意义的革兰氏阳性球菌分离株的体外抗菌活性，2014年在中国17个城市的26家医院连续收集了23.7%的HAP，46.8%的SSTI和29.5%的BSI。这些病原体包括632株耐甲氧西林金黄色葡萄球菌、867株甲氧西林敏感金黄色葡萄球菌、299株凝固酶阴性葡萄球菌（CoNS）、104株粪肠球菌、99株屎肠球菌、13株肺炎链球菌、23株α-溶血性链球菌和103株β-溶血性链球菌。常规临床抗生素的MIC根据临床和实验室标准研究所指南2015通过肉汤微量稀释法测定。替地唑胺、利奈唑胺、万古霉素、达托霉素、替考拉宁和替加环素对革兰氏阳性病原体显示出较高的体外活性（>= 98.0%敏感），而替地唑胺对测试病原体的活性比利奈唑胺高4 - 8倍，对甲氧西林耐药金黄色葡萄球菌、α-溶血性链球菌和β-溶血性链球菌的MIC（90）（0.25 vs 2 μ g ml（-1））;粪肠球菌E.屎肠球菌（0.5 vs 2 μ g ml（-1））;甲氧西林耐药CoNS和甲氧西林敏感CoNS（0.25 vs 1 μ g ml（-1））;肺炎链球菌（0.125 vs 0.5 μ g ml（-1））。与不同感染相关的替地唑胺MIC（90）未显示出显著差异，药物对与HAP、SSTI和BSI相关的革兰氏阳性病原体（包括利奈唑胺不敏感菌株）表现出优异的活性。这些数据表明，替地唑胺可以替代利奈唑胺治疗革兰氏阳性菌引起的感染。
To evaluate the in vitro antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 nonduplicate isolates (23.7% isolated from HAP, 46.8% from SSTI and 29.5% from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant Staphylococcus aureus, 867 methicillin-sensitive Staphylococcus aureus, 299 coagulase-negative Staphylococcus (CoNS), 104 Enterococcus faecalis, 99 Enterococcus faecium, 13 Streptococcus pneumoniae, 23 alpha-haemolytic Streptococcus and 103 beta-haemolytic Streptococcus. MICs of routine clinical antibiotics were determined by broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines 2015. Tedizolid, linezolid, vancomycin, daptomycin, teicoplanin and tigecycline showed high in vitro activity against Gram-positive pathogens (>= 98.0% susceptible), and tedizolid exhibited four-to eight fold greater activity than linezolid against the pathogens tested, with MIC(90)s of methicillin-resistant Staphylococcus aureus, alpha-haemolytic Streptococcus and beta-haemolytic Streptococcus (0.25 vs 2 mu g ml(-1)); methicillin-sensitive Staphylococcusaureus, E. faecalis and E. faecium (0.5 vs 2 mu g ml(-1)); methicillin-resistant CoNS and methicillin-sensitive CoNS (0.25 vs 1 mu g ml(-1)); and Streptococcus pneumoniae (0.125 vs 0.5 mu g ml(-1)). Tedizolid MIC(90)s associated with different infections did not show significant differences, and the drug exhibited excellent activity against surveyed Gram-positive pathogens associated with HAP, SSTI and BSI, including linezolid-nonsusceptible strains. These data suggest that tedizolid could be an alternative to linezolid for the treatment of infections caused by Gram-positive organisms.